Answers are grounded in this paper and cite their sources.
Background B-cell maturation antigen (BCMA) bispecific antibodies have advanced treatment of relapsed/refractory multiple myeloma (RRMM), but comparative data are lacking. Methods An unanchored matching-adjusted indirect comparison (MAIC) was conducted between linvoseltamab and teclistamab in triple-class exposed (TCE) RRMM using patient-level data from LINKER-MM1 (117 patients, linvoseltamab 200 mg, data cutoff 1/2024, median follow-up [mFU] 14.3 months) and aggregate data from MajesTEC-1 (165 patients, teclistamab 1.5 mg/kg, data cutoff 2/2022, mFU 14.1 months). Ten LINKER-MM1 patients with prior BCMA antibody-drug conjugate exposure were excluded to match MajesTEC-1 eligibility criteria. LINKER-MM1 patients were weighted to match MajesTEC-1 on six pre-specified prognostic factors considered most important by an international MM expert panel . Results After matching (effective sample size = 83.0), linvoseltamab showed numerically longer duration of response ( P = 0.100) and significantly longer progression-free survival (PFS, P = 0.004), overall survival (OS, P = 0.039), and time to next treatment ( P = 0.028) than teclistamab based on hazard ratios. Linvoseltamab demonstrated numerically higher objective response rate, very good partial response or better, complete response or better (≥CR), and minimal residual disease–negativity (10 -5 threshold) rates vs teclistamab based on odds ratios. Additional MAICs matching all prognostic factors available in both trials showed significantly longer PFS ( P = 0.038) and OS ( P = 0.039), significantly higher ≥CR ( P = 0.043), and favorable trends for all other outcomes. Conclusion This analysis demonstrated statistically improved PFS and OS and numerically favorable results for all other outcomes for linvoseltamab vs teclistamab in treatment of TCE RRMM. Micro abstract Due to a lack of head-to-head clinical trial data, this study conducted a matching-adjusted indirect comparison of the efficacy of linvoseltamab (LINKER-MM1 trial; 117 patients) and teclistamab (MajesTEC-1 trial; 165 patients) for the treatment of triple-class exposed relapsed/refractory multiple myeloma. Linvoseltamab demonstrated significantly improved progression-free survival and overall survival vs teclistamab, highlighting its potential as a highly effective treatment option.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: